Clinical Trial Search

Primary: Estimated Mean Change From Baseline at Week 4 in 24-hour Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) — -1.3 millimeter of…

Primary: Verbally Administered Numeric Rating Scale (VNRS) — 68; 66 units on a scale — p=0.56

Primary: Change From Baseline in Apnea-Hypopnea Index (AHI) — -25.25; -5.25; -29.27; -5.51 events per hour — p=<0.001

Primary: Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4 — 5.14; 14.94 percentage of time with pH below pH 4 — p=0.0003

Primary: Change From Baseline to Week 12 in ADAS-Cog11 — -2.32; -1.34; -3.01; -2.24 units on a scale

Primary: Presence of Fecal Shedding of Polio Vaccine Virus Determined by Culture (Polio Trial) — 99; 109 Participants — p=0.4

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] — -1.01; -1.00 Percentage of HbA1c

Primary: Change From Baseline in Permanent Product Measure of Performance (PERMP) - Number of Math Problems Answered Correctly (PERMP-C) — 21.8; 18.9 score on a scale

Primary: Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period — 8; 7 Participants

Primary: Successful Conversion to an Organized Heart Rhythm — 28; 39 Participants

Primary: Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48 — 34.6; 49.5 percentage of participants — p=0.0110

Primary: Percentage of HHCs With Virological Influenza Transmission by Day 5 — 13.42; 9.50 percentage of HHCs — p== 0.013

Primary: Number of Patients With Loss of Response With Respect to Hypertension During the RW Phase. — 3; 1; 1; 1 Participants — p=0.0215

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 40; 43 Participants

Primary: Number of Participants With Adverse Events of Margetuximab Plus Retifanlimab in Cohort A, as Assessed by CTCAE v5.0 — 47; 38; 25; 12 Participants